What is NovoCure's restricted cash?

NovoCure (NVCR) reported restricted cash of $9.8M in Q1 2026.

How has NovoCure's restricted cash changed year-over-year?

NovoCure's restricted cash increased by 355.3% year-over-year, from $2.15M to $9.8M.

What is the long-term trend for NovoCure's restricted cash?

Over 5 years (2020 to 2025), NovoCure's restricted cash has grown at a -3.1% compound annual growth rate (CAGR), from $11.5M to $9.84M.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

NovoCure NVCR Restricted Cash

Restricted Cash at other companies

Iovance Biotherapeutics, Inc.IOVA

$5.99M+972%

Syndax PharmaceuticalsSNDX

$102K-53.0%

Ethos Technologies, Inc. LIFE

$1.81M-25.8%

Tango TherapeuticsTNGX

$0-100%

Boston ScientificBSX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's restricted cash?: NovoCure (NVCR) reported restricted cash of $9.8M in Q1 2026.
How has NovoCure's restricted cash changed year-over-year?: NovoCure's restricted cash increased by 355.3% year-over-year, from $2.15M to $9.8M.
What is the long-term trend for NovoCure's restricted cash?: Over 5 years (2020 to 2025), NovoCure's restricted cash has grown at a -3.1% compound annual growth rate (CAGR), from $11.5M to $9.84M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.